Key Takeaways Gilead reached patent settlements with Lupin, Cipla, and Laurus over generic Biktarvy.No Biktarvy generic entry is expected in the U.S. before April 1, 2036.FDA approval of Yeztugo and strong Biktarvy sales drive Gilead's HIV portfolio growth.Gilead Sciences, Inc., (GILD) announced that it has entered into settlement agreements to resolve the patent litigations with a few generic manufacturers who were looking to market generic versions of its flagship HIV treatment, Biktarvy.Biktarvy is one o ...

Gilead stock popped Monday after the biotech giant said it signed deals with three generic drugmakers to delay their Biktarvy copycats for two years.RBC Capital Markets analyst Brian Abrahams called the news a "solid win for GILD to extend their HIV life cycle."Biktarvy is, by far, Gilead Sciences (GILD) biggest moneymaker. The HIV treatment brought in $3.53 billion second-quarter sales. That accounted for more than 69% of the company's HIV sales.Under the deal, generic drugmakers Lupin, Laurus Labs and Cip ...

Gilead Sciences (NASDAQ:GILD) has reached settlement agreements with Lupin, Cipla, and Laurus Labs to resolve patent disputes related to Biktarvy, a medication for HIV. These companies had sought approval from the U.S. Food and Drug Administration to produce generic versions of ...

每经AI快讯，10月6日，吉利德科学股价盘前上涨4.8%。 ...

Key Points Novartis and Gilead Sciences have businesses that can perform well during downturns. Novartis has an extensive portfolio of medicines across many therapeutic areas. Gilead Sciences leads the HIV market and is expanding its oncology lineup. 10 stocks we like better than Novartis › Equity markets experienced significant volatility this year. Many investors feared that President Donald Trump's aggressive trade policies would plunge the economy into a recession and lead to a full-blown sto ...

近期股价表现 - 公司最新收盘价为112.69美元，单日上涨1.93%，表现优于标普500指数的0.01%涨幅，但逊于道琼斯指数的0.51%涨幅，纳斯达克指数当日下跌0.28% [1] - 公司股价在过去一个月下跌1.96%，表现落后于医疗行业4.67%的涨幅和标普500指数4.83%的涨幅 [1] 季度及年度业绩预期 - 市场预计公司下一季度每股收益为2.15美元，同比增长6.44%，但预计季度营收为74.3亿美元，同比下降1.59% [2] - 对于全年业绩，市场共识预期每股收益为8.08美元，同比大幅增长74.89%，预期营收为287.5亿美元，与去年持平 [3] 估值指标分析 - 公司远期市盈率为13.68倍，低于其行业平均的19.42倍，显示其估值相对行业存在折价 [6] - 公司的PEG比率为0.75倍，显著低于其所在医疗生物与遗传学行业1.82倍的平均PEG比率 [7] 行业与评级信息 - 公司所属的医疗生物与遗传学行业在Zacks行业排名中位列第74位，处于所有250多个行业的前30%分位 [7] - 公司当前的Zacks评级为3级（持有），在过去30天内，其每股收益共识预期微幅下调了0.21% [5]

文章核心观点 - 文章作者计划对2026年生物技术行业做出三项非常早期的预测 [1] 作者及其服务 - 作者领导一个名为The Biotech Forum的投资小组 [2] - 该小组提供一个包含12至20只具有高上涨潜力生物技术股票的投资组合模型 [2] - 服务内容包括实时聊天讨论交易想法、每周研究和期权交易 [2]

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best medical stocks to buy now. RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences, Inc. (NASDAQ:GILD) on September 29 and set a price target of $98.00. Why Gilead Sciences (GILD) Deserves Attention in the Cheap Quarterly Dividend Stocks Category Gilead Sciences, Inc. (NASDAQ:GILD) reported a 2% growth in its total revenues for fiscal Q2 2025 to $7.1 billion compared to the same period last year, with management attributing the ...

Investors with a lot of money to spend have taken a bearish stance on Gilead Sciences (NASDAQ:GILD).And retail traders should know.We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with GILD, it often means somebody knows something is about to happen.So how do we know what these investors just did? Today, Benzinga's options scanner ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best large cap value stocks to buy now. On September 22, Morgan Stanley analyst Terence Flynn maintained a Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD), keeping the associated price target the same at $143.00. Why Gilead Sciences (GILD) Deserves Attention in the Cheap Quarterly Dividend Stocks Category The analyst based the optimistic rating on Gilead Sciences, Inc.’s (NASDAQ:GILD) positive outlook and potential growth, reasoning that a notable endor ...